

# Raewyn J Hopkins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8219180/publications.pdf>

Version: 2024-02-01

62  
papers

1,239  
citations

394286

19  
h-index

395590

33  
g-index

62  
all docs

62  
docs citations

62  
times ranked

1878  
citing authors

#	ARTICLE	IF	CITATIONS
1	Airflow Limitation and Histology Shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1060-1067.	2.5	115
2	Individual and Cumulative Effects of GWAS Susceptibility Loci in Lung Cancer: Associations after Sub-Phenotyping for COPD. <i>PLoS ONE</i> , 2011, 6, e16476.	1.1	83
3	The Gutâ€“Liverâ€“Lung Axis. Modulation of the Innate Immune Response and Its Possible Role in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 161-169.	1.4	81
4	Chronic obstructive pulmonary disease (COPD) and lung cancer screening. <i>Translational Lung Cancer Research</i> , 2018, 7, 347-360.	1.3	69
5	Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 35-40.	2.5	63
6	How the genetics of lung cancer may overlap with COPD. <i>Respirology</i> , 2011, 16, 1047-1055.	1.3	61
7	The Relationship between Dietary Fiber Intake and Lung Function in the National Health and Nutrition Examination Surveys. <i>Annals of the American Thoracic Society</i> , 2016, 13, 643-650.	1.5	49
8	Lung Cancer Susceptibility Model Based on Age, Family History and Genetic Variants. <i>PLoS ONE</i> , 2009, 4, e5302.	1.1	47
9	Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trialâ€“American College of Radiology Imaging Network Cohort. <i>Annals of the American Thoracic Society</i> , 2017, 14, 392-402.	1.5	47
10	FAM13A locus in COPD is independently associated with lung cancer &ndash; evidence of a molecular genetic link between COPD and lung cancer. <i>The Application of Clinical Genetics</i> , 2011, 4, 1.	1.4	45
11	Genetic Predisposition to Chronic Obstructive Pulmonary Disease and/or Lung Cancer: Important Considerations When Evaluating Risk. <i>Cancer Prevention Research</i> , 2012, 5, 522-527.	0.7	41
12	Smoking cessation: the potential role of risk assessment tools as motivational triggers. <i>Postgraduate Medical Journal</i> , 2010, 86, 26-33.	0.9	34
13	Diagnosing COPD and targeted lung cancer screening: Figure 1â€“. <i>European Respiratory Journal</i> , 2012, 40, 1063-1064.	3.1	32
14	Link between COPD and lung cancer. <i>Respiratory Medicine</i> , 2010, 104, 758-759.	1.3	29
15	Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 533-544.	1.0	28
16	The sixâ€“minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. <i>Respirology</i> , 2012, 17, 647-652.	1.3	27
17	A review of the Hispanic paradox: time to spill the beans?. <i>European Respiratory Review</i> , 2014, 23, 439-449.	3.0	24
18	Statins as adjunct therapy in COPD: how do we cope after STATCOPE?. <i>Thorax</i> , 2014, 69, 891-894.	2.7	24

#	ARTICLE	IF	CITATIONS
19	Genetic evidence linking lung cancer and COPD: a new perspective. <i>The Application of Clinical Genetics</i> , 2011, 4, 99.	1.4	23
20	Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model. <i>International Journal of Oncology</i> , 2016, 49, 361-370.	1.4	20
21	The Mevalonate Pathway and Innate Immune Hyper-Responsiveness in the Pathogenesis of COPD and Lung Cancer: Potential for Chemoprevention. <i>Current Molecular Pharmacology</i> , 2017, 10, 46-59.	0.7	18
22	A Clinical Practice Guideline Update on the Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2012, 156, 68.	2.0	15
23	Lung Cancer Risk Prediction to Select Smokers for Screening CTâ€”Letter: Figure 1.. <i>Cancer Prevention Research</i> , 2012, 5, 697-698.	0.7	14
24	Prevalence of asthma and atopy in sarcoidosis. <i>Respirology</i> , 2012, 17, 285-290.	1.3	14
25	Is the “Western Diet” a New Smoking Gun for Chronic Obstructive Pulmonary Disease?. <i>Annals of the American Thoracic Society</i> , 2018, 15, 662-663.	1.5	14
26	COPD and Lung Cancer Linked at a Molecular Genetic Level. <i>Chest</i> , 2011, 140, 266-267.	0.4	13
27	Interleukin-6 and statin therapy: potential role in the management of COPD. <i>Respiratory Research</i> , 2013, 14, 74.	1.4	13
28	Recent air travel and venous thromboembolism resulting in hospital admission. <i>Respirology</i> , 2006, 11, 75-79.	1.3	12
29	Estimating Overdiagnosis of Lung Cancer. <i>Annals of Internal Medicine</i> , 2013, 158, 635.	2.0	12
30	The potential impact of chronic obstructive pulmonary disease in lung cancer screening: implications for the screening clinic. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 699-707.	1.0	12
31	Chr15q25 genetic variant (rs16969968) independently confers risk of lung cancer, COPD and smoking intensity in a prospective study of high-risk smokers. <i>Thorax</i> , 2021, 76, 272-280.	2.7	12
32	Targeted CT Image Screening and Its Effect on Lung Cancer Detection Rate. <i>Chest</i> , 2013, 144, 1419-1420.	0.4	11
33	Lower occurrence of idiopathic pulmonary fibrosis in Maori and Pacific Islanders. <i>Respirology</i> , 2006, 11, 467-470.	1.3	10
34	GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?. <i>The Application of Clinical Genetics</i> , 2011, 4, 137.	1.4	9
35	Computed Tomographic Screening for Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1320.	3.8	9
36	Statin Use in Pneumonia. <i>American Journal of Medicine</i> , 2013, 126, e11-e12.	0.6	8

#	ARTICLE	IF	CITATIONS
37	Primary and Secondary Prevention of Chronic Obstructive Pulmonary Disease: Where to Next?. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 839-840.	2.5	8
38	Multi-analyte assays and early detection of common cancers. Journal of Thoracic Disease, 2018, 10, S2165-S2167.	0.6	8
39	Mevalonate signaling, COPD and cancer: the statins and beyond. Journal of Investigative Medicine, 2019, 67, 711-714.	0.7	8
40	Stage Shift in Computed Tomography Screening: Possible Role of Indolent Cancers, "Histology Shift," and Overdiagnosis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1034-1035.	2.5	7
41	Incorporating genomic data into multivariate risk models for lung cancer. Genetics in Medicine, 2013, 15, 667-668.	1.1	7
42	A new alphabet for COPD care: where "E" stands for España. European Respiratory Journal, 2017, 49, 1601970.	3.1	7
43	Characteristics of sarcoidosis in Maori and Pacific Islanders. Respiriology, 2017, 22, 360-363.	1.3	7
44	High Dietary Fiber Lowers Systemic Inflammation: Potential Utility in COPD and Lung Cancer. American Journal of Medicine, 2014, 127, e13.	0.6	6
45	Incorporating Baseline Lung Function in Lung Cancer Screening. Chest, 2021, 159, 1664-1669.	0.4	6
46	Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer, 2013, 119, 1761-1761.	2.0	5
47	Possible Role of Statins in COPD-Related Pulmonary Hypertension. Chest, 2010, 137, 1250-1251.	0.4	4
48	Joint Effect of Single-Nucleotide Polymorphisms and Smoking Exposure in Chronic Obstructive Pulmonary Disease Risk. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 683-683.	2.5	4
49	Statins Reduce Lung Inflammation by Promoting the Clearance of Particulate Matter From Lung Tissues. Chest, 2013, 144, 358-359.	0.4	4
50	Statins and Small Airways Disease in COPD. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 501-501.	1.4	4
51	GWAS in lung disease. Thorax, 2011, 66, 1012-1013.	2.7	3
52	Screening with low-dose computed tomography: Response to The American Association of Thoracic Surgery guidelines. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 307-308.	0.4	3
53	Mortality Reduction, Overdiagnosis, and the Benefit-to-Harm Ratio of Computed Tomography Screening. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 398-399.	2.5	3
54	Is 20% of a loaf enough?. Cancer, 2013, 119, 2815-2815.	2.0	2

#	ARTICLE	IF	CITATIONS
55	CT screening for lung cancer: Figure 1. Thorax, 2012, 67, 650.3-651.	2.7	1
56	Chronic Obstructive Pulmonary Disease Detection During Lung Cancer Screening. JAMA - Journal of the American Medical Association, 2012, 307, 664.	3.8	1
57	Lung Cancer Susceptibility, Ethnicity, and the Benefits of Computed Tomography Screening. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1394-1396.	2.5	1
58	Identifying Patients for Whom Lung Cancer Screening Is Preference-Sensitive. Annals of Internal Medicine, 2018, 169, 822.	2.0	1
59	Reply: The Western Diet: A Smoking Gun for Chronic Obstructive Pulmonary Disease and Asthma?. Annals of the American Thoracic Society, 2018, 15, 1241-1241.	1.5	1
60	Statins Use and Pneumonia. Chest, 2010, 137, 1249.	0.4	0
61	Predictive Accuracy of the Liverpool Lung Project Risk Model. Annals of Internal Medicine, 2013, 158, 568.	2.0	0
62	Statins Reduce Respiratory Complications of COPD. American Journal of Medicine, 2014, 127, e7.	0.6	0